Clever Leaves Teams Up With Hypera Pharma To Supply CBD-Dominant Oral Solutions For Brazilian Patients
Clever Leaves Teams Up With Hypera Pharma To Supply CBD-Dominant Oral Solutions For Brazilian Patients
Clever Leaves Holdings Inc. (NASDAQ:CLVR) (NADAQ:CLVRW) has entered into a five-year agreement with Hypera Pharma (B3:HYPE3) to supply Clever Leaves' CBD-dominant oral solutions with the aim of treating various medical conditions and prescribing to Brazilian patients.
Clever Leaves 控股公司 （納斯達克：CLVR）（NADAQ: CLVRW） 已與 Hypera Pharma 簽訂了爲期五年的協議 (B3: HYPE3) 將提供 Clever Leaves 以CBD爲主的口服溶液 目的是治療各種各樣的 巴西患者的醫療狀況和處方。
Hypera Pharma is one of Brazil's largest pharmaceutical companies in net sales with expertise in the registration, commercialization, and distribution of prescription medicines as well as over-the-counter and skin care products. The CBD products manufactured under this partnership have been registered under RDC 327 framework and are already being sold into distribution channels such as pharmacies and drugstores. The companies plan to continue the process with additional products.
Hypera Pharma是巴西淨銷售額最大的製藥公司之一，在處方藥以及非處方藥和護膚產品的註冊、商業化和分銷方面擁有專業知識。在該合作伙伴關係下生產的CBD產品已在RDC 327框架下注冊，並已銷售到藥店和藥店等分銷渠道。兩家公司計劃繼續這一進程，推出更多產品。
"Hypera Pharma's history, innovative vision, capabilities, focus on high-quality, and commitment to sustainable growth is aligned with Clever Leaves' values, making them an ideal partner to promote and scale patient access to safe, pharmaceutical-grade cannabis products in Brazil. Expanding our presence in Brazil, a market that prioritizes patient treatment by enabling research and development to ensure technical and quality standards, will open doors for potential new developments and is further evidence of how our platform can support the global pharmaceutical industry by allowing it to engage in the world of cannabis-based therapies with patient safety and product quality at the forefront," stated Andres Fajardo, CEO of Clever Leaves.
“Hypera Pharma的歷史、創新願景、能力、對高質量的關注以及對可持續增長的承諾與Clever Leaves的價值觀一致，使他們成爲促進和擴大巴西患者獲得安全藥用級大麻產品的理想合作伙伴。他說：“通過支持研發來確保技術和質量標準，擴大我們在巴西的業務將患者治療放在優先地位，這將爲潛在的新發展打開大門，也進一步證明了我們的平臺如何通過允許全球製藥行業參與將患者安全和產品質量放在首位的大麻類療法領域來爲全球製藥行業提供支持。” 安德烈斯·法哈多，Clever Leaves 首席執行官。
Photo: Benzinga edit with photos by Matthias Zomer on Pexels, squarefrog on Pixabay
照片：Benzinga 在 Pexels 上編輯了 Matthias Zomer 的照片，在 Pixabay 上剪輯了 squarefrog
Related News
相關新聞
Clever Leaves And Praetorian Team Up To Produce Cannabis Genetics In Colombia
Clever Leaves 和 Praetorian 聯手在哥倫比亞生產大麻遺傳學
Clever Leaves Reports Fourth Quarter And Full Year 2022 Results
Clever Leaves 公佈了 2022 年第四季度和全年業績
EXCLUSIVE: House Of Kush Hitting It Out Of The Park For Athletes And The Rest Of Us With Pure Legacy Strains
獨家：House of Kush 用 Pure Legacy Strations 爲運動員和我們其他人大放異彩
譯文內容由第三人軟體翻譯。